Mobile Site ›

PSA Standardization

Arguments for Screening for Prostate Cancer

Slide 6

October 2009

There are several reasons these groups suggest the benefits outweigh the risks with PSA screening. Prostate cancer can be viewed as a significant health burden in the United States, with an estimated 192,280 new cases and 27,360 prostate cancer-related deaths occurring in the United States in 2009.  PSA has a high sensitivity and negative predictive value, depending on what cutoffs are used.  Screening can identify localized disease, before tumors have metastasized, and although controversial, it is argued by some that the cancer detected with screening is significant and likely to progress.  Lastly, countries that screen for prostate cancer have observed a decrease in mortality from the disease itself but have an increased number of individuals diagnosed and subjected to treatment.

Arguments for Screening


Jump to section: